RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

RxSight, Inc.NASDAQ: RXST

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 37.2% from a year ago

Cash & equivalents stood at $17.57M at the end of Q1 FY2026, down 37.2% from a year earlier and down 11.9% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.

Context

  • Cash & equivalents amounted to 5.8% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -37.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.57M-11.9% QoQ
Last fiscal yearDec 2025
$19.95M+19.4% YoY
Year agoMar 2025
$28M-37.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.2%——
1 year+19.4%——
3-year CAGR+19.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
19.95M USD
Year-over-year change
+19.4%
4-year CAGR
-4.9%

Cash & Equivalents vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's Mar 2026 cash & equivalents of $17.57M is the 5th highest of the 9 companies compared; the peer median is $21.31M.
  • Its year-over-year change of -37.2% is the 7th highest of 9, against a peer median of -10.7%.
  • Cash & equivalents amounts to 5.8% of total assets for RXST, versus a peer median of 13.7%.
RXST Competitors Peer median
Cash & Equivalents for RXST and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BFLYButterfly Network, Inc.Mar 2026$137.95M -11.1%-2.5%48.2%
TCMDTactile Systems Technology, Inc.Mar 2026$74.99M -10.3%+56.1%27.6%
DCTHDelcath Systems, Inc.Mar 2026$41.31M +223.4%+78.3%33.1%
CERSCerus CorporationMar 2026$27.85M +43.0%-17.5%12.5%
RXSTRxSight, Inc.Mar 2026$17.57M -37.2%+19.0%5.8%
NPCENeuroPace, Inc.Mar 2026$14.78M -45.3%+48.6%14.9%
KIDSOrthoPediatrics Corp.Mar 2026$14.25M -57.4%+29.6%2.8%
TMCITreace Medical Concepts, Inc.Mar 2026$9.54M -28.6%-18.1%5.2%
DMACDiaMedica Therapeutics Inc.Mar 2026$4.87M +88.0%+49.0%9.2%
Peer median (excluding RXST) $21.31M-10.7%+39.1%13.7%

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents24.36M11.83M9.69M16.71M19.95M
Short-term Investments134.97M93.97M117.49M220.52M208.18M
Net Receivables4.86M10.96M20.28M30.05M23.38M
Inventory8.03M14.84M17.42M22.01M31.56M
Other Current Assets02.96M3.52M4.54M4.39M
Total Current Assets176.3M134.56M168.41M293.82M287.46M
Property, Plant & Equipment (Net)15.5M14.08M13.29M23.63M23.02M
Goodwill00000
Intangible Assets00000
Long-term Investments00711K750K0
Tax Assets00000
Other Non-current Assets925K1.53M147K360K1.34M
Total Non-current Assets16.43M15.61M14.14M24.74M24.36M
Total Assets192.72M150.16M182.55M318.56M311.81M
Account Payables1.69M2.6M3.86M4.54M5.3M
Short-term Debt000974K0
Tax Payables00000
Deferred Revenue618K1.35M2.05M3.11M3.6M
Other Current Liabilities6.92M10.87M2.56M2.79M16.2M
Total Current Liabilities11.08M17.24M20.9M25.88M26.25M
Long-term Debt39.76M40.17M009.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0074K127K0
Total Non-current Liabilities43.4M43.03M1.29M11.45M9.88M
Total Liabilities54.48M60.26M22.19M37.33M36.13M
Common Stock27K28K36K40K41K
Retained Earnings(479.28M)(546.03M)(594.64M)(622.1M)(661.04M)
Accumulated OCI(20K)(95K)(5K)166K53K
Other Stockholders Equity00000
Minority Interest00000
Total Equity138.24M89.9M160.36M281.24M275.68M
Total Debt44.93M45M3.01M12.3M11.04M
Net Debt20.57M33.16M(6.68M)(4.41M)(8.91M)

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.